Bryan E J, Watson R H, Davis M, Hitchcock A, Foulkes W D, Campbell I G
University of Southampton, Princess Anne Hospital, Montreal, Quebec, Canada.
Cancer Res. 1996 Feb 15;56(4):719-21.
The detection of loss of heterozygosity, indicative of the presence of a tumor suppressor gene, has been reported to occur frequently on chromosome 22q in human ovarian cancer. In this study, 110 sporadic ovarian tumors were analyzed using 8 polymorphic loci to define a minimum region of loss. Fifty-eight (53%) tumors showed loss of heterozygosity, and of these 6 exhibited partial loss, enabling the identification of two candidate tumor suppressor gene loci. One region, of less than 0.5 cM, is flanked by D22S284 and CYP2D, and a second region lies distal to D22S276. Analysis of loss of heterozygosity with respect to grade and stage suggests that chromosome 22q loss of heterozygosity is of more relevance in tumor progression rather than initiation.
据报道，杂合性缺失的检测表明存在肿瘤抑制基因，在人类卵巢癌中，这种情况在22号染色体长臂上频繁发生。在本研究中，使用8个多态性位点分析了110例散发性卵巢肿瘤，以确定最小缺失区域。58例（53%）肿瘤显示杂合性缺失，其中6例表现为部分缺失，从而确定了两个候选肿瘤抑制基因位点。一个区域长度小于0.5厘摩，位于D22S284和CYP2D之间，另一个区域位于D22S276的远端。关于分级和分期的杂合性缺失分析表明，22号染色体长臂杂合性缺失在肿瘤进展而非起始过程中更具相关性。
